NCT01443260 2025-04-30
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
Genelux Corporation
Phase 1/2 Completed
Clinical Trials
13 trialsNCT00794131 2025-04-24
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
Genelux Corporation
Phase 1 Completed
NCT03954067 2025-04-22
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT05376527 2025-03-24
Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact
"Oncostar" LLC
Phase 1 Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT01394939 2021-01-08
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1/2 Completed
NCT02562755 2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3 Completed
NCT01169584 2016-01-21
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Phase 1 Completed
NCT01171651 2016-01-20
A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
SillaJen, Inc.
Phase 2 Completed
NCT00625456 2015-12-03
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
SillaJen, Inc.
Phase 1 Completed
NCT01387555 2015-03-11
TRAVERSE
Jennerex Biotherapeutics
Phase 2 Completed
NCT00629759 2013-01-04
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
Jennerex Biotherapeutics
Phase 1 Completed
NCT00116597 2009-12-02
Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
University Hospital, Basel, Switzerland
Phase 1/2 Completed